RxDoctor Payments DataLook up a doctor →

Jason Hafron, MD

Urology · West Bloomfield, MINPI 1255483277

Payments from drug & device makers

$9,884,854in general payments, 2019–2025

Across 1,702 payments — averaging $5807.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$4.2M
  • Janssen Research & Development, LLC$2.5M
  • AstraZeneca$1.1M
  • Pfizer$818K
  • Ortho-clinical Diagnostics, Inc.$337K
  • Siemens Medical Solutions USA, Inc.$264K
  • plus $746K from 54 others
$7,088in research payments, 2019–2025

Across 4 payments — averaging $1772.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dendreon Pharmaceuticals LLC$4K
  • Novartis$3K

What the payments were for

  • Consulting fees$158,08532%
  • Speaking & faculty fees$281,58357%
  • Travel & lodging$30,2006%
  • Food & beverage$19,5094%
  • Education$9140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck205$4,210,910
Janssen Research & Development, LLC423$2,453,592
AstraZeneca42$1,054,994
Pfizer168$818,442
Ortho-clinical Diagnostics, Inc.25$337,187
Siemens Medical Solutions USA, Inc.10$263,611
Sumitomo Pharma America, Inc.66$138,344
Johnson & Johnson(3 entities)132$98,570
Dendreon Pharmaceuticals LLC96$98,321
Myriad Genetic Laboratories, Inc.35$66,448
Organon6$59,200
Urogen Pharma, Inc.35$42,990
Novartis41$38,365
Bayer47$31,042
Astellas Pharma US Inc71$29,510
Amgen51$28,707
Ferring Pharmaceuticals AS1$21,772
Tolmar Pharmaceuticals, Inc.10$13,910
Blue Earth Diagnostics26$13,892
Janssen Global Services, LLC7$10,780
Photocure Inc6$9,790
Progenics Pharmaceuticals, Inc.13$6,546
Janssen Scientific Affairs, LLC12$5,679
Astellas Pharma Global Development3$4,793
Immunitybio, Inc.8$4,027
Myovant Sciences Inc.4$3,932
Procept Biorobotics Corporation7$3,512
AbbVie10$2,758
Exelixis Inc.1$1,980
Sanofi4$1,852
Tolmar, Inc.9$1,733
Intuitive Surgical9$1,481
Verity Pharmaceuticals Inc.17$1,178
Curium US LLC3$777
Medtronic11$769
Ferring Pharmaceuticals Inc.18$751
Boston Scientific9$459
Teleflex LLC4$429
Sun Pharmaceutical Industries Inc.10$225
Bioprotect Medical, Inc.1$165
Neotract Inc.4$158
Tempus AI, Inc2$148
Histosonics, Inc.1$146
Axonics, Inc.1$126
Laborie Medical Technologies Corp.3$121
Clovis Oncology, Inc.3$117
Olympus America Inc.6$114
Antares Pharma, Inc.4$64
Avation Medical, Inc.1$45
Clarus Therapeutics Inc.2$39
BK Medical Holding Company Inc.1$31
Coloplast2$31
Rochester Medical Corporation2$31
Urovant Sciences Inc2$30
Endo Pharmaceuticals Inc.2$29
Ambu Inc.1$25
Angiodynamics, Inc.1$24
Civco Medical Instruments1$23
C. R. Bard, Inc. & Subsidiaries1$23
Endo USA, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,884,854 in reported general payments places this provider in the 95th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$1,055,404
Medicare patients
1,385
Services billed
20,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide179$2,474,044
ErleadaApalutamide133$1,886,036
NubeqaDarolutamide77$1,022,836
Abiraterone Acetate261$346,189
OrgovyxRelugolix104$267,604
MyrbetriqMirabegron78$76,687
GemtesaVibegron45$45,783
Tamsulosin Hcl1,421$33,120
Mirabegron ErMirabegron33$23,964
Finasteride1,037$18,692
Potassium Citrate ErPotassium Citrate26$5,006
Methenamine Hippurate44$4,896
Alfuzosin Hcl ErAlfuzosin Hcl145$4,675
Testosterone32$4,440
Silodosin45$4,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$29,510$2,550,732257 claims
Johnson & JohnsonErleada$98,570$1,886,036133 claims
BayerNubeqa$31,042$1,022,83677 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$5,679$346,189261 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$138,344$313,387149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 urology providers in Michigan.

Other urology in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →